Suppr超能文献

用于筛查和监测结肠镜检查期间腺瘤检测的预测模型的开发与验证,并与实际腺瘤检测率进行比较。

Development and validation of a prediction model for adenoma detection during screening and surveillance colonoscopy with comparison to actual adenoma detection rates.

作者信息

Brand Eelco C, Crook Julia E, Thomas Colleen S, Siersema Peter D, Rex Douglas K, Wallace Michael B

机构信息

Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, United States of America.

Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands.

出版信息

PLoS One. 2017 Sep 28;12(9):e0185560. doi: 10.1371/journal.pone.0185560. eCollection 2017.

Abstract

OBJECTIVE

The adenoma detection rate (ADR) varies widely between physicians, possibly due to patient population differences, hampering direct ADR comparison. We developed and validated a prediction model for adenoma detection in an effort to determine if physicians' ADRs should be adjusted for patient-related factors.

MATERIALS AND METHODS

Screening and surveillance colonoscopy data from the cross-sectional multicenter cluster-randomized Endoscopic Quality Improvement Program-3 (EQUIP-3) study (NCT02325635) was used. The dataset was split into two cohorts based on center. A prediction model for detection of ≥1 adenoma was developed using multivariable logistic regression and subsequently internally (bootstrap resampling) and geographically validated. We compared predicted to observed ADRs.

RESULTS

The derivation (5 centers, 35 physicians, overall-ADR: 36%) and validation (4 centers, 31 physicians, overall-ADR: 40%) cohort included respectively 9934 and 10034 patients (both cohorts: 48% male, median age 60 years). Independent predictors for detection of ≥1 adenoma were: age (optimism-corrected odds ratio (OR): 1.02; 95%-confidence interval (CI): 1.02-1.03), male sex (OR: 1.73; 95%-CI: 1.60-1.88), body mass index (OR: 1.02; 95%-CI: 1.01-1.03), American Society of Anesthesiology physical status class (OR class II vs. I: 1.29; 95%-CI: 1.17-1.43, OR class ≥III vs. I: 1.57; 95%-CI: 1.32-1.86), surveillance versus screening (OR: 1.39; 95%-CI: 1.27-1.53), and Hispanic or Latino ethnicity (OR: 1.13; 95%-CI: 1.00-1.27). The model's discriminative ability was modest (C-statistic in the derivation: 0.63 and validation cohort: 0.60). The observed ADR was considerably lower than predicted for 12/66 (18.2%) physicians and 2/9 (22.2%) centers, and considerably higher than predicted for 18/66 (27.3%) physicians and 4/9 (44.4%) centers.

CONCLUSION

The substantial variation in ADRs could only partially be explained by patient-related factors. These data suggest that ADR variation could likely also be due to other factors, e.g. physician or technical issues.

摘要

目的

腺瘤检出率(ADR)在医生之间差异很大,可能是由于患者群体不同,这妨碍了ADR的直接比较。我们开发并验证了一种腺瘤检测预测模型,以确定是否应针对患者相关因素对医生的ADR进行调整。

材料与方法

使用了横断面多中心整群随机内镜质量改进计划-3(EQUIP-3)研究(NCT02325635)中的筛查和监测结肠镜检查数据。根据中心将数据集分为两个队列。使用多变量逻辑回归建立了检测≥1个腺瘤的预测模型,随后进行了内部(自助重采样)和地理验证。我们比较了预测的ADR和观察到的ADR。

结果

推导队列(5个中心,35名医生,总体ADR:36%)和验证队列(4个中心,31名医生,总体ADR:40%)分别包括9934例和10034例患者(两个队列:48%为男性,中位年龄60岁)。检测≥1个腺瘤的独立预测因素为:年龄(乐观校正比值比(OR):1.02;95%置信区间(CI):1.02-1.03)、男性(OR:1.73;95%CI:1.60-1.88)、体重指数(OR:1.02;95%CI:1.01-1.03)、美国麻醉医师协会身体状况分级(II级与I级相比的OR:1.29;95%CI:1.17-1.43,≥III级与I级相比的OR:1.57;95%CI:1.32-1.86)、监测与筛查(OR:1.39;95%CI:1.27-1.53)以及西班牙裔或拉丁裔种族(OR:1.13;95%CI:1.00-1.27)。该模型的判别能力中等(推导队列中的C统计量为0.63,验证队列为0.60)。观察到的ADR显著低于12/66(18.2%)的医生和2/9(22.2%)的中心预测值,且显著高于18/66(27.3%)的医生和4/9(44.4%)的中心预测值。

结论

ADR的显著差异只能部分由患者相关因素解释。这些数据表明,ADR差异可能也归因于其他因素,如医生或技术问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58b2/5619799/9f50c7eeef25/pone.0185560.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验